We’re looking for women ages 35–42 to participate in The PROGRESS Study.

The hormone progesterone plays a vital role in early pregnancy. Our researchers are investigating an alternative way to administer progesterone with the aim to discover if subcutaneous (under-the-skin) injections are as safe and effective as the current approved medication Crinone®.

Crinone® is a progesterone gel that is administered vaginally and has been approved by the United States Food and Drug Administration, or FDA. The use of Progesterone-IBSA in this study is investigational. An investigational use is one that is not approved by FDA. However, Progesterone-IBSA is already approved and marketed in more than 30 countries worldwide.

The PROGRESS Trial is registered with clinicaltrials.gov, a website run by the National Institutes of Health (NIH) that provides information about clinical trials, and can be found at Clinical Trials NC NCT04549116.